Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2000 2
2001 6
2002 4
2003 3
2004 4
2005 8
2006 7
2007 11
2008 4
2009 4
2010 7
2011 8
2012 11
2013 5
2014 7
2015 12
2016 11
2017 22
2018 9
2019 22
2020 18
2021 23
2022 14
2023 16
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

222 results

Results by year

Filters applied: . Clear all
Page 1
An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs.
Cordell HJ, Fryett JJ, Ueno K, Darlay R, Aiba Y, Hitomi Y, Kawashima M, Nishida N, Khor SS, Gervais O, Kawai Y, Nagasaki M, Tokunaga K, Tang R, Shi Y, Li Z, Juran BD, Atkinson EJ, Gerussi A, Carbone M, Asselta R, Cheung A, de Andrade M, Baras A, Horowitz J, Ferreira MAR, Sun D, Jones DE, Flack S, Spicer A, Mulcahy VL, Byan J, Han Y, Sandford RN, Lazaridis KN, Amos CI, Hirschfield GM, Seldin MF, Invernizzi P, Siminovitch KA, Ma X, Nakamura M, Mells GF; PBC Consortia; Canadian PBC Consortium; Chinese PBC Consortium; Italian PBC Study Group; Japan-PBC-GWAS Consortium; US PBC Consortium; UK-PBC Consortium. Cordell HJ, et al. J Hepatol. 2021 Sep;75(3):572-581. doi: 10.1016/j.jhep.2021.04.055. Epub 2021 May 23. J Hepatol. 2021. PMID: 34033851 Free PMC article.
BACKGROUNDS & AIMS: Primary biliary cholangitis (PBC) is a chronic liver disease in which autoimmune destruction of the small intrahepatic bile ducts eventually leads to cirrhosis. ...CONCLUSIONS: This study has identified additional risk loci for …
BACKGROUNDS & AIMS: Primary biliary cholangitis (PBC) is a chronic liver disease in which autoimmune destruction of …
Carvedilol reduces the risk of decompensation and mortality in patients with compensated cirrhosis in a competing-risk meta-analysis.
Villanueva C, Torres F, Sarin SK, Shah HA, Tripathi D, Brujats A, Rodrigues SG, Bhardwaj A, Azam Z, Hayes PC, Jindal A, Abid S, Alvarado E, Bosch J; Carvedilol-IPD-MA-group and the Baveno Cooperation: an EASL Consortium. Villanueva C, et al. J Hepatol. 2022 Oct;77(4):1014-1025. doi: 10.1016/j.jhep.2022.05.021. Epub 2022 May 31. J Hepatol. 2022. PMID: 35661713 Free article.
We performed a competing-risk time-to-event meta-analysis using individual patient data (IPD) obtained from principal investigators of RCTs. Only compensated patients were included. Primary outcomes were prevention of decompensation (liver transplantation and death …
We performed a competing-risk time-to-event meta-analysis using individual patient data (IPD) obtained from principal investigators of RCTs. …
Primary biliary cirrhosis and cancer risk: a systematic review and meta-analysis.
Liang Y, Yang Z, Zhong R. Liang Y, et al. Hepatology. 2012 Oct;56(4):1409-17. doi: 10.1002/hep.25788. Epub 2012 Aug 27. Hepatology. 2012. PMID: 22504852 Review.
Several studies have indicated that primary biliary cirrhosis (PBC) may be associated with increased risk of some cancers, but the results are controversial. ...
Several studies have indicated that primary biliary cirrhosis (PBC) may be associated with increased risk of some cance …
Cholestatic Pruritus Treatments in Primary Biliary Cholangitis and Primary Sclerosing Cholangitis: A Systematic Literature Review.
Smith HT, de Souza AR, Thompson AH, McLaughlin MM, Dever JJ, Myers JA, Chen JV. Smith HT, et al. Dig Dis Sci. 2023 Jun;68(6):2710-2730. doi: 10.1007/s10620-023-07862-z. Epub 2023 Mar 18. Dig Dis Sci. 2023. PMID: 36933112 Free PMC article.
BACKGROUND AND AIMS: We conducted a systematic literature review to understand the evidence supporting treatment decisions for cholestatic pruritus associated with primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC). ...
BACKGROUND AND AIMS: We conducted a systematic literature review to understand the evidence supporting treatment decisions for cholestatic p …
Systematic review and meta-analysis: bezafibrate in patients with primary biliary cirrhosis.
Yin Q, Li J, Xia Y, Zhang R, Wang J, Lu W, Zhou Y, Zheng Y, Abudumijiti H, Chen R, Chen K, Li S, Liu T, Wang F, Lu J, Zhou Y, Guo C. Yin Q, et al. Drug Des Devel Ther. 2015 Sep 30;9:5407-19. doi: 10.2147/DDDT.S92041. eCollection 2015. Drug Des Devel Ther. 2015. PMID: 26491252 Free PMC article. Review.
BACKGROUND AND AIM: Ursodeoxycholic acid (UDCA) is the standard treatment for primary biliary cirrhosis (PBC), but not all cases respond well. Evidence has shown that combination therapy of UDCA with bezafibrate significantly improved liver function. . …
BACKGROUND AND AIM: Ursodeoxycholic acid (UDCA) is the standard treatment for primary biliary cirrhosis (PBC), but not …
Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: A systematic review and meta-analysis.
Clements O, Eliahoo J, Kim JU, Taylor-Robinson SD, Khan SA. Clements O, et al. J Hepatol. 2020 Jan;72(1):95-103. doi: 10.1016/j.jhep.2019.09.007. Epub 2019 Sep 16. J Hepatol. 2020. PMID: 31536748
RESULTS: A total of 13 risk factors were selected from 25 case-control studies in 7 geographically diverse countries. The strongest risk factors for both iCCA and eCCA were biliary cysts and stones, cirrhosis, hepatitis B and hepatitis C. ...LAY SUMMARY: Cholangioca …
RESULTS: A total of 13 risk factors were selected from 25 case-control studies in 7 geographically diverse countries. The strongest risk fac …
Systematic Review: The Epidemiology, Natural History, and Burden of Alagille Syndrome.
Kamath BM, Baker A, Houwen R, Todorova L, Kerkar N. Kamath BM, et al. J Pediatr Gastroenterol Nutr. 2018 Aug;67(2):148-156. doi: 10.1097/MPG.0000000000001958. J Pediatr Gastroenterol Nutr. 2018. PMID: 29543694 Free PMC article.
RESULTS: Of 525 screened publications, 20 met the inclusion criteria. Liver-related features included cholestasis (87%-100% of patients), jaundice (66%-85%), and cirrhosis (44%-95%). Between 15% and 47% of patients underwent liver transplantation and 4% to 14 …
RESULTS: Of 525 screened publications, 20 met the inclusion criteria. Liver-related features included cholestasis (87%-100% of patien …
Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review.
Boonstra K, Beuers U, Ponsioen CY. Boonstra K, et al. J Hepatol. 2012 May;56(5):1181-1188. doi: 10.1016/j.jhep.2011.10.025. Epub 2012 Jan 13. J Hepatol. 2012. PMID: 22245904 Free article. Review.
OBJECTIVE: Studies on the epidemiology of primary sclerosing cholangitis (PSC) and primary biliary cirrhosis (PBC) show variable outcome. ...
OBJECTIVE: Studies on the epidemiology of primary sclerosing cholangitis (PSC) and primary biliary cirrhosis (PB …
Long-Term Impact of Iatrogenic Bile Duct Injury.
Schreuder AM, Busch OR, Besselink MG, Ignatavicius P, Gulbinas A, Barauskas G, Gouma DJ, van Gulik TM. Schreuder AM, et al. Dig Surg. 2020;37(1):10-21. doi: 10.1159/000496432. Epub 2019 Jan 17. Dig Surg. 2020. PMID: 30654363 Free PMC article.
After initial management of BDI, patients stay at risk for late complications including anastomotic strictures, recurrent cholangitis, and secondary biliary cirrhosis. METHODS: We provide a comprehensive overview of current literature on the long-term outcome of BDI …
After initial management of BDI, patients stay at risk for late complications including anastomotic strictures, recurrent cholangitis, and s …
Treatment response to ursodeoxycholic acid in primary biliary cholangitis: A systematic review and meta-analysis.
Gazda J, Drazilova S, Gazda M, Janicko M, Koky T, Macej M, Carbone M, Jarcuska P. Gazda J, et al. Dig Liver Dis. 2023 Oct;55(10):1318-1327. doi: 10.1016/j.dld.2022.12.010. Epub 2022 Dec 31. Dig Liver Dis. 2023. PMID: 36593158 Review.
BACKGROUND: Several ursodeoxycholic acid (UDCA) treatment response definitions have been introduced in primary biliary cholangitis (PBC). However, the lack of a gold standard results in heterogeneity in second-line treatment research and clinical practice. ...Howeve …
BACKGROUND: Several ursodeoxycholic acid (UDCA) treatment response definitions have been introduced in primary biliary cholang …
222 results